The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Insights into the REMoDL-A trial: acalabrutinib plus R-CHOP for patients with DLBCL
In this video, Vivek Radhakrishnan, MD, MBSS, MCRCP, University Hospital Southampton NHS Foundation Trust, Southampton, UK, shares some insights into the ongoing Phase II REMoDL-A trial (NCT04546620), which is evaluating acalabrutinib in combination with R-CHOP for patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Dr Radhakrishnan highlights the importance of evaluating the molecular pathophysiology of DLBCL to develop novel treatments, and further discusses the rationale behind combining acalabrutinib with R-CHOP in this patient population. To conclude, Dr Radhakrishnan comments on how the DLBCL treatment landscape is evolving with novel agents. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
